Suppliers / Zaklady Farmaceutyczne Polpharma

Zaklady Farmaceutyczne Polpharma

Poland Updated 9 July 2026

Zaklady Farmaceutyczne Polpharma is an API and finished-dose manufacturer based in Poland. It holds 41 active US drug master files. Its filings concentrate with EMA, MPA (SE) and AEMPS (ES). Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 25 May 2018 as VAI.

41
active US DMFs
0
valid CEPs
4
registered plants 1 with an FDA FEI number
784
filings across 9 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 25 May 2018 VAI US FDA
  • 29 January 2015 NAI US FDA
  • 20 September 2012 NAI US FDA
  • 29 January 2009 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Poland, Poland 3002807920
Sieradz, Poland Not on file
Blonie, Poland Not on file
STAROGARD GDANSKI, Poland Not on file

What they file, and where

Molecule Regulators Docs
Aripiprazole US FDA 2
Carvedilol US FDA 2
Dapagliflozin US FDA 2
Hydrochlorothiazide SFDA (Saudi Arabia), US FDA 2
Ticagrelor SFDA (Saudi Arabia), US FDA 2
Abemaciclib US FDA 1
Acetazolamide US FDA 1
Alendronic Acid US FDA 1
Apixaban US FDA 1
Apremilast US FDA 1
Show all 30 molecules on file
Aripiprazole Lauroxil US FDA 1
Avanafil US FDA 1
Baclofen US FDA 1
Baricitinib US FDA 1
Brexpiprazole US FDA 1
Carbamazepine US FDA 1
Empagliflozin US FDA 1
Enzalutamide US FDA 1
Etodolac US FDA 1
Ibandronate US FDA 1
Isavuconazonium US FDA 1
Lamotrigine US FDA 1
Linagliptin US FDA 1
Oxcarbazepine US FDA 1
Palbociclib US FDA 1
Pentoxifylline US FDA 1
Pimavanserin US FDA 1
Rivaroxaban US FDA 1
Sacubitril/Valsartan US FDA 1
Safinamide US FDA 1

Also appears on these molecule pages

Show 53 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 737 5
MPA (SE) 24 None
AEMPS (ES) 9 None
ARCSA (EC) 4 None
FAMHP (BE) 4 None
ANSM (FR) 2 None

Questions about Zaklady Farmaceutyczne Polpharma

Does Zaklady Farmaceutyczne Polpharma hold a US DMF or a CEP?
Zaklady Farmaceutyczne Polpharma holds 41 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zaklady Farmaceutyczne Polpharma FDA-registered?
One site operated by Zaklady Farmaceutyczne Polpharma carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zaklady Farmaceutyczne Polpharma's last inspection go?
The most recent inspection on record closed on 25 May 2018 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 4 inspections are on file.
Where does Zaklady Farmaceutyczne Polpharma manufacture?
4 registered sites are on record, in Poland (Poland, Sieradz and Blonie among others). Every site is listed on this page with the register it came from.
What does Zaklady Farmaceutyczne Polpharma make?
30 molecules are on record against Zaklady Farmaceutyczne Polpharma, including Aripiprazole, Carvedilol, Dapagliflozin and Hydrochlorothiazide. Each links through to that molecule's full manufacturer list.
Which regulators recognise Zaklady Farmaceutyczne Polpharma's GMP?
Current GMP certificates are on record from EMA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zaklady Farmaceutyczne Polpharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 3 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 25 May 2018.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates